Doctorate in Business Administration (DBA) from Paris School of Business

One of China's 30 Most Influential Investors, Honorary President of the Hong Kong Association of Pharmaceutical Innovation, Founding Member of the Investment Committee of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), Member of the BayHelix Group, and Distinguished Lecturer at Duke Kunshan University.

With over a decade of experience in the investment industry, he has focused on the biopharmaceutical sector, contributing to the advancement of the pharmaceutical industry. He has led investments in Heyuan Biosciences, Chipscreen Biosciences, Ascentage Pharma, Frontier Biotechnologies, Genuine Biotech, Qyuns Therapeutics, and others.

His accolades include:

• CHC · Top 50 Most Influential Investors of the Year

• FOF Weekly · Top 20 Best Healthcare Investors of 2023

• CHC · Top 50 Most Influential Investors of 2022

• ChinaVenture · Top 100 Chinese Best Venture Capitalists of 2021

• Best Investor in the Medical and Health Industry 2020

• China Financial Person of the Year Top 5 2019